Sign in Subscribe
COVID-19

Childhood Cancer Survivors at Higher Risk for Severe COVID-19 Infection

Strategic Insights

— 1 min read

Childhood cancer survivors face a significant risk of severe COVID-19 infection, despite having a lower risk of contracting the virus in the first place, according to a recent study published in The Lancet Regional Health: Europe. Researchers analyzed a large cohort of childhood cancer survivors and compared their rates of COVID-19 infection and severity to those of the general population. The findings suggest that childhood cancer survivors, who already have a compromised immune system due to their cancer treatment, may require special protection during periods of high viral transmission.

Key Takeaways:

  • Childhood cancer survivors have a lower risk of contracting COVID-19 (adjusted hazard ratio, 0.91) but a higher risk of severe COVID-19 (adjusted hazard ratio, 1.58) compared to the general population.
  • The elevated risk of severe COVID-19 was particularly evident during periods of widespread viral transmission.
  • The researchers found that 13,659 childhood cancer survivors, 58,803 matched comparators, and 17,531 siblings were included in the cohort.
  • The study suggests that childhood cancer survivors should be considered a high-risk group in future pandemics or health crises, and may require prioritization for vaccination or special protection during high transmission periods.
  • The findings highlight the need for personalized healthcare and protection strategies for vulnerable populations, such as childhood cancer survivors.

Statistics:

  • 13,659 childhood cancer survivors were included in the study.
  • 58,803 matched comparators were included in the study.
  • 17,531 siblings of childhood cancer survivors were included in the study.
  • The risk for registered COVID-19 infection was significantly lower for childhood cancer survivors compared with comparators (adjusted hazard ratio, 0.91).
  • The risk for severe COVID-19 was higher for childhood cancer survivors compared with comparators (adjusted hazard ratio, 1.58).

Sources:

  • The Lancet Regional Health: Europe
  • Karolinska Institutet in Stockholm
  • HealthDay News (July 11, 2025)

Read more